The Motley Fool's CAPS investing service is great way for investors to work together to beat the market -- and maybe get famous while they're at it. Among its features, CAPS encourages users to blog about their picks, investing strategy, market view, their favorite ice cream flavor, or whatever floats their boat.

As the CAPS blogosphere continues to grow, players are adding more great content on a daily basis. To make it easier to find some of the gems out there, I've dug through the past week's posts to find some of CAPS' best insights. Of course, with room for only seven posts here I can't possibly cover all of the great stuff in the CAPS blogosphere. So when you're done here I highly recommend heading over to CAPS and checking out what some of the other investors have to say.

The kind of things I'll be looking for
Russell Carpenter aka TMFEldrehad has been one of the most successful members of the massive CAPS community, posting a score of nearly 7,000 and an accuracy of above 80%. His EldrehadsPicks profile is no slouch either. Now he's leaving. Oh no, not forever, just for a vacation in Austria. But before he bolts, he took some time to talk about a number of things including the market craziness, his involvement with the new Motley Fool Pro, and what he learned from shorting DryShips (NASDAQ:DRYS). Click through to Russell's blog for the full scoop.

A modern interpretation of the ant and the grasshopper
What can a famous fable tell us about auto giants Toyota (NYSE:TM) and General Motors (NYSE:GM)? If you ask CAPS blogger TMFDeej, a whole lot. TMFDeej has revamped this classic tale for today's situation in the auto industry. Go ahead and head over to his blog for this story of how to do it right and how to get it oh so wrong in the automotive world.

Seven stocks for the impending apocalypse
CAPS member TheHuney thinks that if it's all gloom and doom that investors might as well be taking risks. For that reason, TheHuney has highlighted seven stocks -- such as Mosaic (NYSE:MOS) and North American Palladium -- that he thinks are selling at a "steep discount." Head over to TheHuney's blog for the rest of the list.

The new bear market: Darwin's market
What's there to like about a bear market? Well, if you think about it the way BuffettBoy2 does, there's plenty to like. As BuffettBoy points out, these market and economic downturns work like a weeding out process giving us an economic survival of the fittest. And as outoffocus pointed out in a comment, the same goes for weeding out the weakest investors. Check out BuffettBoy's blog to find out exactly why he wants to change the phrase "bear market" to "Darwin market."

Too big to exist!
Are companies like JPMorgan (NYSE:JPM) and Citigroup really too big to fail? Not if you ask ThatGuy73 -- he thinks they're too big to have existed in the first place. Check out ThatGuy's solution to the current crisis by clicking through to his blog.

Generic drug industry outpaces drug and health carehealth care ETFs
In turmoil like we've been witnessing lately, many investors think that health carehealth care stocks can provide at least some shelter from the storm. So what should we be looking at? Heavy hitters like Pfizer (NYSE:PFE) with big dividends and category-killer drugs like Lipitor? That's not what InvestRx thinks. He thinks you should be looking at generic drug manufacturers like Teva and Mylan. Head over to InvestRx's blog to find out why.

I'm convinced! Investors are ignorant!
Crisis? What crisis? At least that's how Varchild2008 looks at it after seeing companies like IBM and Johnson & Johnson (NYSE:JNJ) beat their earnings estimates. Is it really not as bad as it seems? Head over to Varchild's blog for a take on the current environment.

And that's our round-up for this week. Be sure to check back next week for more great blogging action. In the meantime, why not head over to CAPS and add your two cents to the community pool?

More CAPS Foolishness:

Pfizer, JPMorgan Chase, and Johnson & Johnson are Motley Fool Income Investor selections. Pfizer is a Motley Fool Inside Value pick. The Fool owns shares of Pfizer. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Matt Koppenheffer does not own shares of any of the companies mentioned. The Fool''s disclosure policy is still waiting for its bailout.